GlobeNewswire by notified

Novartis presents new data in breast and prostate cancer at ESMO

Share
  • Overall survival results from pooled exploratory analysis of MONALEESA trials in patients with aggressive HR+/HER2- advanced breast cancer treated with Kisqali®
  • Data from VISION study reporting associations between magnitude of PSA decline from baseline and clinical outcomes with Pluvicto® in patients with mCRPC
  • Overall survival and safety findings for first-line tislelizumab in unresectable hepatocellular carcinoma from RATIONALE 301, the eighth positive clinical trial readout for tislelizumab

Basel, August 30, 2022 — Novartis will showcase new data from across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2022 with over 35 accepted abstracts from Novartis-sponsored and investigator-initiated trials including new data in advanced breast cancer and metastatic castration-resistant prostate cancer.

“We are excited to share the data being presented across our portfolio of cancer therapies, which reinforce our commitment to pursuing every possible approach to address the urgent and significant unmet medical needs of people living with cancer,” said Jeff Legos, Executive Vice President, Global Head of Oncology & Hematology Development, Novartis. “Our presentations at ESMO will highlight our continued dedication to advancing innovative treatment options for these critical diseases.”

Key highlights of data accepted by ESMO:

MedicineAbstract TitleAbstract Number/ Presentation Details
Kisqali® (ribociclib)*

Pooled exploratory analysis of survival in patients (pts) with HR+/HER2− advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials
Abstract #205P
Poster Session
Saturday, September 10

Kisqali® (ribociclib)*

HARMONIA SOLTI-2101 / AFT-58: A head-to-head phase III study comparing ribociclib (RIB) and palbociclib (PAL) in patients with hormone receptor-positive/HER2-negative/HER2-Enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC)

Abstract # 272TiP
Poster Session
Saturday, September 10
Piqray® (alpelisib) BYLieve trial (alpelisib [ALP] + endocrine therapy [ET]) versus real-world (RW) standard of care (SOC) in patients (pts) with PIK3CA-mutated (mut), hormone receptor-2 positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced 3 breast cancer (ABC) who progressed on cyclin-dependent kinase 4/6 inhibitor (CDKi) 4 therapy (tx)

Abstract #222P
Poster Session
Saturday, September 10

Tislelizumab​

Final Analysis of RATIONALE-301: Randomized, Phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Abstract #LBA36
Proffered Paper Session
Saturday, September 10
09:15 – 09:25 AM CEST

Tislelizumab​ Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study

Abstract #1031P
Poster Session
Monday, September 12

Pluvicto™ (lutetium 177Lu vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial Abstract #1372P
Poster Session
Sunday, September 11

Pluvicto™ (lutetium 177Lu vipivotide tetraxetan) Radiographic progression-free survival correlation with patient-relevant outcomes: a post hoc analysis of time-to-event endpoints of the VISION trial

Abstract #1374P
Poster Session
Sunday, September 11,

Prostate Cancer Quality of life across three countries using a large-scale, fully digital survey of patients with prostate cancer 

Abstract #1401P
Poster Session
Sunday, September 11

Canakinumab
(ACZ885)
CANOPY-A: phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)

Abstract #LBA49
Proffered Paper Session
Sunday, September 11
09:20 – 09:30 AM CEST

Vijoice® (alpelisib) Clinical benefit of alpelisib in pediatric patients with PIK3CA-related overgrowth spectrum (PROS): an EPIK-P1 analysis

Abstract #468P
Poster Session
Monday, September 12

Product Information
For full prescribing information, including approved indications and important safety information about marketed products, please visit
https://www.novartisoncology.com/news/product-portfolio.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

# # #

* Kisqali was developed by the Novartis Institutes for BioMedical Research (NIBR) under a research collaboration with Astex Pharmaceuticals.
† Investigator-initiated trial

Novartis Media Relations
E-mail: media.relations@novartis.com

Anja von Treskow
Novartis External Communications
+41 79 392 8697 (mobile)
anja.von_treskow@novartis.com



Julie Masow
Novartis US External Communications
+1 862 579 8456
Julie.masow@novartis.com

Michael Billings
Novartis Oncology Communications
+1 862 778 8656 (direct)
+1 201 400 1854 (mobile)
michael.billings@novartis.com



Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

Central North America
Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440
Nicole Zinsli-Somm +41 61 324 3809 Alina Levchuk +1 862 778 3372
Isabella Zinck +41 61 324 7188 Parag Mahanti +1 973-876-4912
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Chief People Officer, Amy Hanlon-Rodemich to leave Nokia28.3.2024 15:15:00 CET | Press release

Nokia Corporation Stock Exchange Release 28 March 2024 at 16:15 EET Chief People Officer, Amy Hanlon-Rodemich to leave Nokia Espoo, Finland – Nokia today announces that its Chief People Officer, Amy Hanlon-Rodemich, will leave the company and step down from its Group Leadership Team. A recruitment process will begin immediately for her successor and Amy will retain an advisory role during her notice period. Amy joined Nokia in 2022 and has been key to renewing the company’s people services and employee experience. “This has been a difficult decision for me to take. I’ve enjoyed my time at Nokia and am looking forward to the next chapter in my career. I wish everyone at Nokia continued success,” commented Amy. “I would like to thank Amy for her contributions to Nokia and leadership of the People organisation. I wish her all the best with her future endeavours,” said Pekka Lundmark, President and CEO of Nokia. Lorna Gibb, Vice President, Labor & Employment, will assume the role of interi

Fenix Outdoor: Fenix Outdoor International AG Årsredovisning samt Hållbarhetsrapport 202328.3.2024 15:00:00 CET | Pressemelding

Zug 2024-03-28 Press meddelande - Årsredovisning samt Hållbarhetsrapport 2023 Bifogat Års- och Hållbarhetsredovisning för 2023. Årsredovisningen skiljer sig från Q4 pressmeddelandet på en punkt. Bokslutskommuniké Årsredovisning Nyttjanderättstillgångar MEUR 130,5 MEUR 117,2 Summa tillgångar MEUR 743,2 MEUR 729,9 Skillnaden består i tillägget av ett tyskt hyreskontrakt förlängt från 2024-01-01, undertecknat 2023. Inga effekter i resultaträkningen för 2023. Bilagor feni-2023-12-31-enAnnual_Report_2023Årsredovisning_2023CSR_2023

Fenix Outdoor: Fenix Outdoor International AG Annual and CSR report 202328.3.2024 15:00:00 CET | Press release

Zug 2024-03-28 Pressrelease - Annual and CSR report 2023 Attached Annual and CSR report 2023. The annual report differs from the Q4 press release in one position. Q4 Press release Annual Report Right of Use asset MEUR 130.5 MEUR 117,2 Total Asset MEUR 743.2 MEUR 729.9 The reason for the difference is the addition of a German lease contract prolonged from 2024-01-01, signed in 2023. No effects in Income statement for 2023. Attachments feni-2023-12-31-enAnnual_Report_2023Årsredovisning_2023CSR_2023

eQ Plc Managers' Transactions – Staffan Jåfs28.3.2024 15:00:00 CET | Press release

eQ Plc Managers' Transactions 28 March 2024 at 4:00 p.m. Person subject to the notification requirement Name: Staffan Jåfs Position: Other senior manager Issuer: eQ Oyj LEI: 743700R4FA6AVH5J3D68 Notification type: INITIAL NOTIFICATION Reference number: 57077/4/4 ____________________________________________ Transaction date: 2024-03-26 Outside a trading venue Instrument type: SHARE ISIN: FI0009009617 Nature of transaction: SUBSCRIPTION (X) Linked to stock option programme Transaction details (1): Volume: 65000 Unit price: 3.62 EUR Aggregated transactions (1): Volume: 65000 Volume weighted average price: 3.62 EUR eQ Plc Additional information: Juha Surve, Group General Counsel, tel. +358 9 6817 8733 Distribution: Nasdaq Helsinki, www.eQ.fi eQ Group is a Finnish group of companies specialising in asset management and corporate finance business. eQ Asset Management offers a wide range of asset management services (including private equity funds and real estate asset management) for institu

Exterro Hires Rick Valentine as New Chief Customer Officer28.3.2024 14:00:00 CET | Press release

Seasoned executive will focus on ensuring Exterro customers maximize the value of their investment PORTLAND, Ore., March 28, 2024 (GLOBE NEWSWIRE) -- Exterro, the leading provider of data risk management software solutions, today announced the appointment of Rick Valentine, an expert in delivering world-class customer experiences at global organizations, as its new chief customer officer. The appointment reflects Exterro’s long-term commitment to delivering an outstanding experience and return on investment to all customers using its data risk management platform. Valentine will report directly to Exterro CEO Bobby Balachandran. Valentine brings more than three decades of leadership experience to the CCO position, most recently as chief customer officer at data management company Quantum. His prior executive experience encompasses both large public enterprises and high-growth startups in the high-tech space, including Silver Peak Systems/HPE, Veritas/Symantec, and Intuit. Valentine bri

HiddenA line styled icon from Orion Icon Library.Eye